p21WAF1/CIP1 and cancer: A shifting paradigm?
The DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.
Abstract
The cyclin‐dependent kinase inhibitor p21 WAF1/CIP1 is a key mediator of p53‐dependent cell cycle arrest and may play the role of a tumor suppressor in cancer. However, it has been shown that p21 may also act as an oncogene, because it inhibits apoptosis and may promote cell proliferation in some tumors. These data point out to “antagonistic duality” of p21, because it possesses anticancer and procancer properties at the same time. New data suggest that more and more proteins also may play contradictory roles in cancer thus challenging current paradigm of established oncogenes and tumor suppressors. © 2009 International Union of Biochemistry and Molecular Biology, Inc.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
New functional activities for the p21 family of CDK inhibitors.
LaBaer, J., Garrett, M. D., Stevenson, L. F., Slingerland, J. M., Sandhu, C., Chou, H. S., Fattaey, A., & Harlow, E. (1997) · Genes & Development · doi:10.1101/gad.11.7.847 · Cited by 1,402
Cheng, M., Olivier, P., Diehl, J. A., Fero, M., Roussel, M. F., Roberts, J. M., & Sherr, C. J. (1999) · The EMBO Journal · doi:10.1093/emboj/18.6.1571 · Cited by 1,142 · cited 2×
“They demonstrated that after transfer p21 accumulated in the nucleus of ODG tumor cells and promoted the formation of cyclin D–cdk4 complexes [29,30], thus contributing to increased proliferation and reduced apoptosis in tumors [27].”
BackgroundDisruption of p53 in human cancer cells alters the responses to therapeutic agents.
Bunz, F., Hwang, P. M., Torrance, C., Waldman, T., Zhang, Y., Dillehay, L., Williams, J., Lengauer, C., Kinzler, K. W., & Vogelstein, B. (1999) · Journal of Clinical Investigation · doi:10.1172/jci6863 · Cited by 1,044 · cited 1×
“p21 usually plays inhibitory role in apoptosis [8,41,42], but in some cases [43–45] it induces cell death [8,10].”
BackgroundDose-dependent oncogene-induced senescence in vivo and its evasion during mammary tumorigenesis
Sarkisian, C. J., Keister, B. A., Stairs, D. B., Boxer, R. B., Moody, S. E., & Chodosh, L. A. (2007) · Nature Cell Biology · doi:10.1038/ncb1567 · Cited by 490 · cited 1×
“One of the major oncogenes, Ras, may activate tumor suppressor pathways and trigger an irreversible senescent growth arrest [48].”
BackgroundLiu, G., Parant, J. M., Lang, G., Chau, P., Chavez-Reyes, A., El-Naggar, A. K., Multani, A., Chang, S., & Lozano, G. (2004) · Nature Genetics · doi:10.1038/ng1282 · Cited by 325 · cited 1×
“Previously, it has been shown that knock-in mice with p53R172P mutant (instead of p53) have prolonged survival compared to p53-null mice [21].”
BackgroundDNA damage-induced cellular senescence is sufficient to suppress tumorigenesis: a mouse model
Van Nguyen, T., Puebla-Osorio, N., Pang, H., Dujka, M. E., & Zhu, C. (2007) · The Journal of Experimental Medicine · doi:10.1084/jem.20062453 · Cited by 72 · cited 2×
“Other groups [18,19] used p53 mouse mutant p53R172P (corresponding to human p53R175P) [20] that lost its ability to induce apoptosis, but retained its capacity to induce p21 and cell cycle arrest to address the role of p21 in cancer [12].”
Background
Cited by
The Multifaceted p21 (Cip1/Waf1/CDKN1A) in Cell Differentiation, Migration and Cancer Therapy
Kreis, N.-N., Louwen, F., & Yuan, J. (2019) · Cancers · doi:10.3390/cancers11091220 · Cited by 298
Krifka, S., Spagnuolo, G., Schmalz, G., & Schweikl, H. (2013) · Biomaterials · doi:10.1016/j.biomaterials.2013.03.019 · Cited by 289
Brodowska, K., Al-Moujahed, A., Marmalidou, A., Meyer zu Horste, M., Cichy, J., Miller, J. W., Gragoudas, E., & Vavvas, D. G. (2014) · Experimental Eye Research · doi:10.1016/j.exer.2014.04.011 · Cited by 220
Primary cilia and coordination of receptor tyrosine kinase (RTK) signalling
Christensen, S. T., Clement, C. A., Satir, P., & Pedersen, L. B. (2012) · The Journal of Pathology · doi:10.1002/path.3004 · Cited by 181
The lauric acid-activated signaling prompts apoptosis in cancer cells
Lappano, R., Sebastiani, A., Cirillo, F., Rigiracciolo, D. C., Galli, G. R., Curcio, R., Malaguarnera, R., Belfiore, A., Cappello, A. R., & Maggiolini, M. (2017) · Cell Death Discovery · doi:10.1038/cddiscovery.2017.63 · Cited by 169
Hypoxia and succinate antagonize 2-deoxyglucose effects on glioblastoma
Pistollato, F., Abbadi, S., Rampazzo, E., Viola, G., Puppa, A. D., Cavallini, L., Frasson, C., Persano, L., Panchision, D. M., & Basso, G. (2010) · Biochemical Pharmacology · doi:10.1016/j.bcp.2010.08.003 · Cited by 51
“cell death [44], revealed that GBM cells exposed to 20% oxygen, independently from addition of 2-DG, had a higher p21 cip1 level compared to cells maintained under hypoxia,”
BackgroundEsteras, N., Alquézar, C., Bermejo-Pareja, F., Bialopiotrowicz, E., Wojda, U., & Martín-Requero, Á. (2013) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2012.10.014 · Cited by 25
Metadata
- Authors
- Gartel, A. L.
- Venue
- BioFactors
- Publisher
- Wiley
- Published
- 2009-03
- Volume
- 35
- Issue
- 2
- Pages
- 161-164
- ISSN
- 0951-6433 (ISSN-L)
- 1872-8081
- OpenAlex
- W2003744982
- Cited by
- 71
- References
- 6
- FWCI
- 4.18
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.